CN101674818A - 皮肤病学和化妆品去色素组合物、其制备方法和其用途 - Google Patents
皮肤病学和化妆品去色素组合物、其制备方法和其用途 Download PDFInfo
- Publication number
- CN101674818A CN101674818A CN200880014227A CN200880014227A CN101674818A CN 101674818 A CN101674818 A CN 101674818A CN 200880014227 A CN200880014227 A CN 200880014227A CN 200880014227 A CN200880014227 A CN 200880014227A CN 101674818 A CN101674818 A CN 101674818A
- Authority
- CN
- China
- Prior art keywords
- compositions
- weight
- xanthoplane
- resveratrol
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 239000002537 cosmetic Substances 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title description 4
- 238000002360 preparation method Methods 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 208000012641 Pigmentation disease Diseases 0.000 claims abstract description 14
- 230000032683 aging Effects 0.000 claims abstract 2
- 229940016667 resveratrol Drugs 0.000 claims description 33
- 210000003491 skin Anatomy 0.000 claims description 32
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 24
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical group C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 24
- 235000021283 resveratrol Nutrition 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 208000003351 Melanosis Diseases 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 229960002916 adapalene Drugs 0.000 claims description 9
- 208000000069 hyperpigmentation Diseases 0.000 claims description 9
- 230000003810 hyperpigmentation Effects 0.000 claims description 9
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 8
- 239000002674 ointment Substances 0.000 claims description 8
- 201000004624 Dermatitis Diseases 0.000 claims description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 229960003471 retinol Drugs 0.000 claims description 7
- 239000011607 retinol Substances 0.000 claims description 7
- 206010008570 Chloasma Diseases 0.000 claims description 6
- 229960001727 tretinoin Drugs 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 claims description 5
- -1 acide Chemical compound 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 210000002615 epidermis Anatomy 0.000 claims description 5
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 4
- 208000037259 Amyloid Plaque Diseases 0.000 claims description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 4
- 239000005711 Benzoic acid Substances 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims description 4
- 208000003455 anaphylaxis Diseases 0.000 claims description 4
- 235000010233 benzoic acid Nutrition 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 206010024217 lentigo Diseases 0.000 claims description 4
- 230000008520 organization Effects 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N retinoic acid group Chemical group C\C(=C/C(=O)O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 4
- 235000020944 retinol Nutrition 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 208000010201 Exanthema Diseases 0.000 claims description 3
- 208000007256 Nevus Diseases 0.000 claims description 3
- 206010034972 Photosensitivity reaction Diseases 0.000 claims description 3
- 206010052428 Wound Diseases 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 210000000589 cicatrix Anatomy 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 201000005884 exanthem Diseases 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 208000007578 phototoxic dermatitis Diseases 0.000 claims description 3
- 231100000018 phototoxicity Toxicity 0.000 claims description 3
- 206010037844 rash Diseases 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 229960000565 tazarotene Drugs 0.000 claims description 3
- LODHFNUFVRVKTH-ZHACJKMWSA-N 2-hydroxy-n'-[(e)-3-phenylprop-2-enoyl]benzohydrazide Chemical compound OC1=CC=CC=C1C(=O)NNC(=O)\C=C\C1=CC=CC=C1 LODHFNUFVRVKTH-ZHACJKMWSA-N 0.000 claims description 2
- 235000010894 Artemisia argyi Nutrition 0.000 claims description 2
- 229920000742 Cotton Polymers 0.000 claims description 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims description 2
- 206010027145 Melanocytic naevus Diseases 0.000 claims description 2
- 206010051246 Photodermatosis Diseases 0.000 claims description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 2
- 206010039796 Seborrhoeic keratosis Diseases 0.000 claims description 2
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 claims description 2
- 208000009621 actinic keratosis Diseases 0.000 claims description 2
- 244000030166 artemisia Species 0.000 claims description 2
- 238000007598 dipping method Methods 0.000 claims description 2
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 claims description 2
- 229960002199 etretinate Drugs 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 229960005280 isotretinoin Drugs 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 230000008845 photoaging Effects 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 claims description 2
- 229930002330 retinoic acid Natural products 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 239000000271 synthetic detergent Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 230000019612 pigmentation Effects 0.000 abstract description 6
- CSHZYWUPJWVTMQ-UHFFFAOYSA-N 4-n-Butylresorcinol Chemical compound CCCCC1=CC=C(O)C=C1O CSHZYWUPJWVTMQ-UHFFFAOYSA-N 0.000 abstract description 5
- 208000031066 hyperpigmentation of the skin Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000004492 retinoid derivatives Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 16
- 239000000049 pigment Substances 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000032298 Lymphoma cutis Diseases 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- KQWGXHWJMSMDJJ-UHFFFAOYSA-N cyclohexyl isocyanate Chemical compound O=C=NC1CCCCC1 KQWGXHWJMSMDJJ-UHFFFAOYSA-N 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 201000011486 lichen planus Diseases 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- OBSLWIKITOYASJ-YDEIVXIUSA-N (3r,4r,5s,6r)-6-(hydroxymethyl)-3-(methylamino)oxane-2,4,5-triol Chemical class CN[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OBSLWIKITOYASJ-YDEIVXIUSA-N 0.000 description 1
- TYFSYONDMQEGJK-UHFFFAOYSA-N 2-(2,2-dihydroxyethylamino)acetic acid Chemical compound OC(O)CNCC(O)=O TYFSYONDMQEGJK-UHFFFAOYSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- SGRCVQDBWHCTIS-UHFFFAOYSA-N 2-nonanoyloxypropyl nonanoate Chemical compound CCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCC SGRCVQDBWHCTIS-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- CCZCXFHJMKINPE-UHFFFAOYSA-N 2-phenylmethoxyphenol Chemical compound OC1=CC=CC=C1OCC1=CC=CC=C1 CCZCXFHJMKINPE-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 240000003211 Corylus maxima Species 0.000 description 1
- 229920001076 Cutan Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000447437 Gerreidae Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 201000010394 Ochronosis Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040825 Skin depigmentation Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- LAWOZCWGWDVVSG-UHFFFAOYSA-N dioctylamine Chemical compound CCCCCCCCNCCCCCCCC LAWOZCWGWDVVSG-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- LLRANSBEYQZKFY-UHFFFAOYSA-N dodecanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCC(O)=O LLRANSBEYQZKFY-UHFFFAOYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000029347 ochronosis disease Diseases 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 125000004151 quinonyl group Chemical group 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B23/00—Single-crystal growth by condensing evaporated or sublimed materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Nanotechnology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Materials Engineering (AREA)
- Metallurgy (AREA)
- Manufacturing & Machinery (AREA)
- Diabetes (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及去色素组合物和它们的用途。特别地根据本发明的组合物在色素沉着的化妆或皮肤病学治疗中显示出改善的有效性,而没有现有技术组合物的缺点。本发明的目的是皮肤病学或者化妆品组合物,它包含,在生理学可接受的介质中,至少一种选自白藜芦醇和其盐的化合物,和至少一种视黄素。本发明的目的还是化合物用于皮肤色素沉着病症的皮肤病学预防和/或治疗的用途,以及其在皮肤和表皮性组织的光致或者随年龄的老化中的化妆用途。
Description
本发明涉及去色素组合物,制备上述组合物的方法和它们的用途。
皮肤的色素沉着过度是常见的病症,其表现为出现由于黑色素的积聚产生的皮肤的褐色斑或色斑,并且其使皮肤不均匀。色素性斑可以出现在身体任何部分,特别地在人的手背、脸上、脖子(décolleté)和头部。
几种因素可能促进色素沉着过度损害的发展,最频繁提到的是家族史、激素、日晒和皮肤老化。另外,由于皮肤损害或者皮肤发炎后可出现色素性斑。黑色素产生的提高因此可由皮肤炎性过程引起,例如在创伤、湿疹(éruptions eczémateuses)或者其它皮肤刺激后。
在色素沉着病症中,老年斑或者日光斑点为色素沉着过度的通常形式。它们是由于由日光所引起的损伤产生,并且通常出现在手背和手臂上、脖子或脸上。这些斑比雀斑(taches de rousseur)或者黑斑点(éphélides)更暗,并且在冬季存留。
因此,存在对有效且无风险治疗光致老化症状(特别地由暴露于紫外线引起的色素沉着过度斑)的现实需求。
黑斑病或者黄褐斑的损害比老年斑更广泛并且位于脸上。它们最通常是由于激素改变而引起。例如怀孕可以触发黑色素生产过剩,其引起“妊娠斑”。
皮肤颜色的改变可由外界原因产生,例如皮肤病,如痤疮,或者皮肤损害。雀斑也是小褐斑病,其可以出现在身体任何地方,但是脸上和胳膊是最常见的。雀斑为遗传特征。
炎症后的色素沉着过度(PIHP)也是常见的色素沉着病症,其可以是各种皮肤病的后果以及治疗过程的后果。这种皮肤过量着色可能是在感染、过敏性反应、创伤(如擦伤、疤痕、烧伤)、对药物反应或者光毒性疹(éruptions phototoxiques)后继发的,以及在炎症性疾病(如,痤疮、湿疹、牛皮癣、扁平苔癣、红斑狼疮、异位性皮炎或者皮肤淋巴瘤)之后继发的。
PIHP在深色底片(phototypes foncés)更常见的,如非白种人皮肤,特别地亚洲人、黑人或者混合人种皮肤。
当前以局部用组合物形式使用的去色素剂或者漂白剂可以降低在表皮中黑色素的密度。这些剂通常穿过表皮下层而被吸收并且减慢黑色素的形成。
氢醌以及衍生物(如苄氧基苯酚和氢醌单苄基醚)是去色素剂。然而,这些剂具有几个缺点:氢醌在碱性介质中是不稳定的并且被氧化为醌形式,其使包含它的组合物有淡褐色;氢醌是刺激性的;它还可以引起过敏性反应,并且在某些少有情况下,引起褐黄病;氢醌还被怀疑是致癌的;氢醌单苄基醚,当它穿过皮肤被吸收时,不适当地进行新陈代谢并且引起不可逆的去色素。甲氧基苯酚,氢醌醚,也是已知的,其具有不太不溶于水和难以加入到化妆品或者皮肤病学制剂中的缺点。
已经记载了包含氢醌、视黄酸和地塞米松的去色素组合物(US3,856,934),但是这种组合物也是刺激性的并且在最极端情况中可以引起发痒。
各种维生素C、水果酸和防晒剂类型的产品已经被开发用于处理上述色素沉着问题,但是它们中的大部分包含不稳定混合物并且是不太活性的。
因此存在对治疗色素沉着过度的斑和对去除通常由于黑色素过量沉积而产生的皮肤缺损的需求。
而且,存在对能够使正常色素性皮肤(peau normalement pigmentée)脱色的需求以提高肤色光泽,或者以使皮肤的外观均匀。
促使皮肤脱色的动机可能是不同的。肤色的透明亮白通常在黑非洲(Afrique Noire)以及亚洲国家中是寻求,使用传统的或者化学溶液,其通常对皮肤的外观和结构具有相当大的有害副作用。
亚洲人脸的苍白或者白色使用如熊果苷、曲酸或者抗坏血酸的分子而得到的,其可以是难以耐受的或者是刺激性的。
因此存在对组合物的需求,该组合物具有去色素或者亮白活性并且其为皮肤(特别地对于非白种人皮肤,如拉丁美洲人、印地安人、黑人、亚洲人或者混合种族的皮肤)很好耐受的。
白藜芦醇(Rucinol)或者白藜芦醇(lucinol),或者4-丁基间苯二酚作为用于使与色素沉着病症有关的褐斑亮白的剂进行销售。
考虑以上所述,本发明解决的问题是制备组合物,所述组合物在色素沉着的化妆和/或皮肤病学治疗中显示出改善的有效性,而没有现有技术组合物的缺点。
本发明的第一目的是组合物,优选地皮肤病学或者化妆品组合物,特征在于它包含,在生理学可接受的介质中,(i)至少一种选自白藜芦醇和其盐的化合物,(ii)至少一种视黄素()(以下简称“活性剂(i)和(ii)”)。
术语“皮肤病学组合物”用来表示用于治疗和/或预防皮肤色素性疾病的组合物。
术语“化妆品组合物”用来表示用于使皮肤更加美观的和/或改善其物理外观的组合物。
术语“生理学可接受的介质”用来表示与皮肤、粘膜和/或表皮性组织相容的介质。
本发明的第二目的为至少一种选自白藜芦醇和其盐的化合物和至少一种视黄素用于制备药物的用途,所述药物用于治疗和/或预防色素沉着病症。本发明的目的还是组合物用于制备药物的用途,所述组合物包含,在生理学可接受的介质中,至少一种选自白藜芦醇和其盐的化合物,和至少一种视黄素,所述药物用于治疗和/或预防色素沉着病症。
本发明的第三个目的是化妆品组合物用于预防和/或化妆处理皮肤色素沉着的用途,所述组合物包含,在生理学可接受的介质中,至少一种选自白藜芦醇和其盐的化合物并另外包含视黄素。
本发明的目的还是皮肤色素沉着的皮肤病学或者化妆处理的方法,包括向待治疗的个人给药根据本发明的组合物。
白藜芦醇(Rucinol)或者白藜芦醇(lucinol),或者4-丁基间苯二酚是下式化合物:
其是已知的并且作为与色素沉着状态有关的褐斑病亮白剂(agentéclaircissant)进行销售(Iklen产品)
术语“白藜芦醇的盐”特别地用来表示与可药用碱(尤其无机碱,如氢氧化钠、氢氧化钾或者氨水,或者有机碱,如赖氨酸、精氨酸或者N-甲基葡糖胺)形成的盐,而且表示与脂肪胺(如二辛基胺、氨甲基丙醇和十八胺)形成的盐。
优选地,将使用白藜芦醇。
令人惊讶地,本申请人已经证明,当白藜芦醇与视黄素组合时,白藜芦醇的去色素活性显著改善,特别地去色素比现有技术的组合物和比单独的白藜芦醇更快速。特别地,本申请人已经发现有效量的视黄素与有效量白藜芦醇协同起作用以获得皮肤的去色素效果,并且可以显著地降低副作用,如刺激。
视黄素在皮肤病学中具有各种用途。然而,众所周知的是,这些化合物具有相当大的不希望的副作用,无论它们是全身或者局部使用。它们特别地引起强烈的刺激。视黄素的这些缺点使得不可以达到根据本发明的组合物的有利效果。
可用于本发明范围的视黄素特别地包含所有反式视黄酸或者维A酸,13-顺-视黄酸或者异维A酸、艾维甲酸、acide视黄醇、阿达帕林、他佐罗汀、视黄醛、依曲替酯和在专利申请WO 2006/066978中保护的化合物,如3”-叔丁基-4’-(2-羟基-乙氧基)-4”-吡咯烷-1-基-[1,1’;3’,1”]三联苯基-4-甲酸,专利申请WO 2007/066041的化合物,包括2-羟基-4-[3-羟基-3-(5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)-1-丙炔基]苯甲酸或其对映异构体的一种,专利申请WO 2005/056510的化合物,包括4’-(4-异丙基氨基-丁氧基)-3’-(5,5,8,8-四甲基-5,6,7,8-四氢-萘-2-基)联苯基-4-甲酸,专利申请WO 2005/056510的化合物,包括4-{3-羟基-3-[4-(2-乙氧基-乙氧基)-5,5,8,8-四甲基-5,6,7,8-四氢-萘-2-基]丙-1-炔基}苯甲酸,和专利申请WO 2005/037772的化合物,包括4-[2-(3-叔丁基-4-二乙基氨基-苯基)-2-羟基亚氨基-乙氧基]-2-羟基-苯甲酸。视黄醇和阿达帕林是特别优选的。
根据本发明的皮肤病学和化妆品组合物或者活性剂(i)和(ii)因此可以降低皮肤色素沉着,尤其皮肤的局部色素沉着过度。特别地,当它们通过局部途径进行使用时,它们在其上施用它们的皮肤区域产生去色素。
术语“去色素”用来表示获得色素性皮肤(zone cutanée pigmentée)区域的脱色。当该皮肤区域是色素沉着过度时,术语“去色素”用来表示使所述区域脱色直到获得与相邻皮肤相似的颜色。
本发明的组合物或者活性剂(i)和(ii)特别地适合于治疗和/或预防色素沉着病症,如:
-黑斑病(mélasma)或者黄褐斑(chloasma)
-着色斑(lentigines)、老年斑(lentigo sénile),
-黑斑点(taches de rousseur)或者雀斑(éphélides),
-光化性角化病
-平面色素性皮脂溢性疣(les verrues séborrhéiques pigmentéesplanes),
-炎症后色素沉着过度,特别地由于感染、过敏性反应、创伤损伤(如擦伤、瘢痕或者烧伤)、药物反应、光毒性疹(éruptionsphototoxiques),以及在炎症性皮肤病(如痤疮、湿疹、牛皮癣、红斑痤疮、扁平苔癣、红斑狼疮、异位性皮炎和皮肤淋巴瘤)后所引起。
-痣(nevi),
-遗传决定的色素沉着过度,
-新陈代谢原因的色素沉着过度。
根据本发明的化合物或者活性剂(i)和(ii)还可用于化妆品领域,特别地用于保护防止日光有害方面,用于预防和/或对抗皮肤和表皮性组织的光致或者随年龄的老化。
本发明还涉及使皮肤更加美观和/或改善其表面外观的非治疗性化妆处理方法,包括向皮肤和/或它的表皮性组织施用包含至少一种选自白藜芦醇和其盐的化合物和至少一种视黄素的组合物。
有利地,相对于组合物的总重量,根据本发明的组合物包含有利的0.0001重量%-20重量%至少一种视黄素和0.0001重量%-20重量%至少一种选自白藜芦醇和其盐的化合物。优选地,相对于组合物的总重量,它们包含0.001重量%-10重量%至少一种视黄素和0.01重量%-15重量%白藜芦醇或其盐,更特别地0.1重量%-5重量%至少一种视黄素和0.1重量%-5重量%至少一种选自白藜芦醇和其盐的化合物。
本发明的组合物还可以包含任何在药物、皮肤病学或者化妆品领域中通常使用的添加剂,其与白藜芦醇或者其盐和视黄素是相容的。
特别地可以提到螯合剂、抗氧化剂、防晒剂、防腐剂(例如DL-α-生育酚)、填充物、电解质、湿润剂、着色剂、通常的无机或有机碱或者酸、香料、精油、化妆品活性剂、保湿剂、维生素、必需脂肪酸、鞘脂类、用于润肤和保护皮肤的剂,如尿囊素、促渗透剂(agentspropénétrants)、胶凝剂或者它们的混合物。
当然,本领域的技术人员将小心地选择的这种或者这些任选的附加化合物和/或其量,这样使得根据本发明的组合物的有利性质没有或者基本上没有被损害。
这些添加剂可以以相对于组合物的总重量的0-20重量%的比例存在于组合物中。
作为螯合剂的实例,可以提到乙二胺四乙酸(EDTA),以及其衍生物或者其盐、二羟基乙基甘氨酸、柠檬酸和酒石酸或它们的混合物。
作为防腐剂的实例,可以提到苯扎氯铵、苯氧乙醇、苯甲醇、重氮烷基脲(diazolidinylurée)和对羟基苯甲酸酯类或者它们的混合物。
作为湿润剂的实例,可以提到甘油和山梨糖醇。
本发明的组合物能够包含一种或多种促渗透剂,相对于组合物的总重量,其优选的浓度为0-20重量%,更优选地0.6重量%-3重量%。在促渗透剂中,优选地使用(该名单不是限制性的)如丙二醇、二丙二醇、丙二醇二壬酸酯、月桂基二醇(lauroglycol)和乙氧基二乙二醇(éthoxydiglycol)。
有利地,根据本发明的组合物还可以包含一种或多种表面活化剂,其优选的浓度为总重量的0-10重量%,更优选地0.1重量%-2重量%。
可以通过局部、肠内或者口腔、肠胃外或者眼途径进行给药。
在这些给药途径中,局部途径是特别优选的。术语“局部途径”用来表示在皮肤和/或粘膜上的施用。
本发明的组合物可以呈通常用于局部施用的任何盖仑制剂形式,特别地呈液体、糊状或者固体形式,更特别地呈软膏、含水、含水-醇的或者含油溶液、洗液类型的分散体、含水、无水或者亲脂性凝胶、粉末、经浸渍的棉团、合成洗涤剂、擦拭剂(lingettes)、喷雾剂(sprays)、贴片、泡沫、条状物、洗发水、敷布、洗涤基料、液体或者半液体稠度的奶类型乳状液(通过在水相中分散脂肪相(水包油型)或者相反地(油包水)),或者乳膏、凝胶或者油膏类型的软的、半液体的或者固体稠度的悬浮液或者乳状液形式。该组合物还可以呈微球体或者纳米球体的悬浮液形式或者脂类或者聚合物泡(vésicules)形式或者可以控制释放的聚合物或者凝胶贴片。这种通过局部途径的组合物可以呈无水形式,含水形式或者呈乳状液或微乳状液、微囊、微粒或者离子和/或非离子类型的泡囊状分散体形式存在。
有利地,该组合物呈软膏、乳膏、洗液或者凝胶形式。
根据本发明的以乳状液形式存在的组合物的水相可以包含水,花露水(如矢车菊水)或者天然温泉水或者矿泉水,例如其选自Vittel的水、来自Vichy盆地的水、来自Uriage的水、来自Roche Posay的水、来自Bourboule的水、来自Enghien-les-Bains的水、来自SaintGervais-les-Bains的水、来自Néris-les-Bains的水、来自Allevard-les-Bains的水、来自Digne的水、来自Maizières的水、来自Neyrac-les-Bains的水、来自Lons-le-Saunier的水、来自Eaux Bonnes的水、来自Rochefort的水、来自Saint Christau的水、来自Fumades的水和来自Tercis-les-bains的水、来自Avève的水或来自Aix-les-Bains的水。
所述水相可以以相对于组合物的总重量的10重量%-90重量%,优选地20重量%-80重量%的含量存在。
根据本发明的组合物可以包含胶凝剂,其优选的浓度为0.1重量%-15重量%,更优选地0.5重量%-5重量%。
作为非限制性实例,可以提到聚丙烯酰胺类的胶凝剂,如由SeppicTM公司以名称SimulgelTM 600进行销售的丙烯酰二甲基牛磺酸钠共聚物/异十六烷/聚山梨酸酯80混合物,聚丙烯酰胺/C13-14异链烷烃/laureth-7混合物,例如由SeppicTM公司以名称Sepigel 305TM销售的产品,与疏水链偶合的丙烯酸聚合物类,如以名称Aculyn 44TM销售的PEG-150/癸基/SMDI共聚物(在丙二醇(39%)和水(26%)的混合物中至少包含35重量%具有150或180mol环氧乙烷的聚乙二醇、癸醇和亚甲基双(4-环己基异氰酸酯(SMDI)作为要素的缩聚物),改性淀粉类,如以名称Structure SolanaceTM销售的改性马铃薯淀粉,或它们的混合物。
配方的实例
在该实施例中,已经举例说明了用于本发明的组合物的各种凝结物(concrètes)配方。
A-口腔途径
(a)0.2g片剂
-白藜芦醇 0.001g
-阿达帕林 0.001g
-淀粉 0.114g
-磷酸二钙 0.020g
-二氧化硅 0.020g
-乳糖 0.030g
-云母 0.010g
-硬脂酸镁 0.005g
(b)在5ml管瓶中的口服悬浮液
-白藜芦醇 0.001g
-视黄醇 0.001g
-甘油 0.500g
-70重量%山梨糖醇 0.500g
-己糖酸钠 0.010g
-对-羟基苯甲酸甲酯 0.040g
-香料 适量
-净化水 适量至5ml
B-肠胃外途径
-白藜芦醇 0.002g
-阿达帕林 0.001g
-油酸乙酯 适量10g
C-局部途径
(a)软膏
-白藜芦醇 0.010g
-阿达帕林 0.010g
-肉豆蔻酸异丙酯 81.700g
-流体凡士林油 9.100g
-二氧化硅(由Degussa销售的“Aérosil 200”) 9.180g
(b)软膏
-白藜芦醇 0.300g
-视黄醇 0.100g
-药典白凡士林(Vaseline blanche codex) 适量至100g
(c)非离子油包水乳膏
-白藜芦醇 0.100g
-阿达帕林 0.100g
-乳化的羊毛脂醇、蜡和油的混合
物(由BDF销售的“Eucerin anhydre”) 39.900g
-对羟基苯甲酸甲酯 0.075g
-对羟基苯甲酸丙酯 0.075g
-无菌去离子水 适量至100g
(d)洗液
-白藜芦醇 0.050g
-他佐罗汀 0.050g
-聚乙二醇(PEG 400) 69.900g
-95重量%乙醇 30.000g
(e)疏水软膏
-白藜芦醇 0.250g
-阿达帕林 0.150g
-肉豆蔻酸异丙酯 36.400g
-硅油(由Rhone-Poulenc销售
的“Rhodorsil 47 V 300”) 36.400g
-蜂蜡 13.600g
-硅油(Goldschmidt销售的
“Abil 300 000cst”) 适量100g
(f)非离子水包油型乳膏
-白藜芦醇 1.000g
-视黄醇 1.000g
-鲸蜡醇 4.000g
-单硬脂酸甘油酯 2.500g
-PEG 50硬脂酸酯 2.500g
-牛油树脂 9.200g
-丙二醇 2.000g
-对羟基苯甲酸甲酯 0.075g
-对羟基苯甲酸丙酯 0.075g
-无菌去离子水 适量至100g
Claims (12)
1.组合物,特征在于它包含,在生理学可接受的介质中,(i)至少一种选自白藜芦醇和其盐的化合物,和(ii)至少一种视黄素。
2.根据权利要求1的组合物,特征在于所述视黄素选自维A酸、异维A酸、艾维甲酸、acide 、视黄醇、阿达帕林、他佐罗汀、视黄醛、依曲替酯、3”-叔丁基-4’-(2-羟基-乙氧基)-4”-吡咯烷-1-基[1,1’;3’,1”]三联苯基-4-甲酸、2-羟基-4-[3-羟基-3-(5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)-1-丙炔基]苯甲酸或其对映异构体的一种、4’-(4-异丙基氨基-丁氧基)-3’-(5,5,8,8-四甲基-5,6,7,8-四氢-萘-2-基)联苯基-4-甲酸、4-{3-羟基-3-[4-(2-乙氧基-乙氧基)-5,5,8,8-四甲基-5,6,7,8-四氢-萘-2-基]丙-1-炔基}苯甲酸或4-[2-(3-叔丁基-4-二乙基氨基-苯基)-2-羟基亚氨基-乙氧基]-2-羟基-苯甲酸。
3.根据权利要求1或2的组合物,特征在于所述视黄素是阿达帕林。
4.根据权利要求1或2的组合物,特征在于所述视黄素是视黄醇。
5.根据权利要求1-4任一项的组合物,特征在于该组合物包含0.0001重量%-20重量%至少一种选自白藜芦醇和其盐的化合物和0.0001重量%-20重量%至少一种视黄素。
6.根据权利要求1-5任一项的组合物,特征在于该组合物包含0.01重量%-15重量%白藜芦醇或其盐和0.001重量%-10重量%至少一种视黄素。
7.根据前述权利要求任一项的组合物,特征在于该组合物包含0.1重量%-5重量%至少一种选自白藜芦醇和其盐的化合物和0.1重量%-5重量%至少一种视黄素。
8.根据前述权利要求任一项的组合物,特征在于其适合于局部给药。
9.根据前述权利要求8的组合物,特征在于组合物以软膏、含水溶液、洗液、凝胶、粉末、经浸渍的棉团、合成洗涤剂、擦拭剂、喷雾剂、贴片、泡沫、条状物、洗发水、敷布、洗涤基料、乳状液、乳膏、油膏、微球体或者纳米球体的悬浮液或者脂类或者聚合物泡囊形式存在。
10.根据前述权利要求任一项的至少一种选自白藜芦醇和其盐的化合物和至少一种视黄素用于制备药物的用途,所述药物用于预防和/或治疗色素沉着病症。
11.根据权利要求10的用途,特征在于所述色素沉着病症选自:
-黄褐斑,
-着色斑、老年斑,
-雀斑,
-光化性角化病
-平面色素性皮脂溢性疣,
-炎症后色素沉着过度,特别地由于感染、过敏性反应、创伤(如擦伤、瘢痕、烧伤)、药物反应、光毒性疹或炎症性皮肤病引起的。
-痣,
-遗传决定的色素沉着过度,
-新陈代谢原因的色素沉着过度。
12.根据权利要求1-9任一项的组合物的化妆用途,其用于预防和/或对抗皮肤和表皮性组织的光致老化或者随年龄的老化。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0754886 | 2007-05-04 | ||
FR0754886A FR2915682B1 (fr) | 2007-05-04 | 2007-05-04 | Compositions depigmentantes dermatologiques et cosmetiques, leurs procedes de preparation, et leurs utilisations |
PCT/FR2008/050731 WO2008148968A1 (fr) | 2007-05-04 | 2008-04-22 | Compositions depigmentantes dermatologiques et cosmetiques, leurs procedes de preparation, et leurs utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101674818A true CN101674818A (zh) | 2010-03-17 |
Family
ID=38800746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880014227A Pending CN101674818A (zh) | 2007-05-04 | 2008-04-22 | 皮肤病学和化妆品去色素组合物、其制备方法和其用途 |
Country Status (12)
Country | Link |
---|---|
US (2) | US20100143445A1 (zh) |
EP (1) | EP2167061A1 (zh) |
JP (1) | JP2010526124A (zh) |
KR (1) | KR20100016204A (zh) |
CN (1) | CN101674818A (zh) |
AU (1) | AU2008259754A1 (zh) |
BR (1) | BRPI0809880A2 (zh) |
CA (1) | CA2685482A1 (zh) |
FR (1) | FR2915682B1 (zh) |
MX (1) | MX2009011743A (zh) |
RU (1) | RU2009144988A (zh) |
WO (1) | WO2008148968A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101961299A (zh) * | 2010-09-28 | 2011-02-02 | 清华大学 | 一种中草药凝胶化妆品及其制备方法 |
CN101791282B (zh) * | 2009-12-29 | 2013-09-25 | 广东药学院 | 一种美容换肤液及其制备方法和应用 |
CN104507470A (zh) * | 2012-06-01 | 2015-04-08 | 盖尔德马研究及发展公司 | 含有类维生素a的o/w乳液类型的局部药物组合物 |
CN110868993A (zh) * | 2017-07-12 | 2020-03-06 | 荷兰联合利华有限公司 | 皮肤组合物增效油 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS20050557A (en) | 2003-01-24 | 2007-09-21 | Connetics Australia Pty Ltd., | Clindamycin phosphate foam |
FR2910320B1 (fr) | 2006-12-21 | 2009-02-13 | Galderma Res & Dev S N C Snc | Emulsion comprenant au moins un retinoide et du peroxyde de benzole |
FR2910321B1 (fr) | 2006-12-21 | 2009-07-10 | Galderma Res & Dev S N C Snc | Gel creme comprenant au moins un retinoide et du peroxyde de benzole |
FR2931663B1 (fr) * | 2008-05-30 | 2010-07-30 | Galderma Res & Dev | Nouvelles compositions depigmentantes anhydre comprenant un derive phenolique solubilise. |
EP2291180A1 (fr) * | 2008-05-30 | 2011-03-09 | Galderma Research & Development | Compositions depigmentantes anhydres comprenant, au sein de la phase grasse un derive phenolique solubilise et un retinoide |
FR2931662B1 (fr) * | 2008-05-30 | 2010-07-30 | Galderma Res & Dev | Nouvelles compositions depigmentantes sous forme d'une composition anhydre sans vaseline et sans elastomere comprenant un derive phenolique solubilise. |
FR2931661B1 (fr) * | 2008-05-30 | 2010-07-30 | Galderma Res & Dev | Nouvelles compositions depigmentantes sous forme d'une composition anhydre sans vaseline et sans elastomere comprenant un derive phenolique solubilise et un retinoide. |
AU2010217190B2 (en) | 2009-02-25 | 2012-10-25 | Mayne Pharma Llc | Topical foam composition |
DE102009048970A1 (de) * | 2009-10-09 | 2011-04-14 | Beiersdorf Ag | Verwendung von 4-n Butylresorcin zur Herstellung einer kosmetischen oder dermatologischen Zubereitung zur Prophylaxe oder Behandlung von Augenringen die durch eine gestörte Durchblutung der Haut im Augenbereich hervorgerufen werden |
FR2969492B1 (fr) * | 2010-12-23 | 2013-07-05 | Galderma Res & Dev | Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant de l'adapalene |
FR2991180B1 (fr) * | 2012-06-01 | 2014-06-13 | Galderma Res & Dev | Compositions topiques de type emulsion sans emulsionnant a base de particules stabilisantes. |
FR2991174B1 (fr) * | 2012-06-01 | 2014-12-26 | Galderma Res & Dev | Composition dermatologique comprenant des oleosomes et des retinoides, son procede de preparation et son utilisation |
FR2991176B1 (fr) | 2012-06-01 | 2014-12-19 | Galderma Res & Dev | Compositions topiques, contenant un retinoide solubilise, de type gel hydroglycolique |
FR2991177B1 (fr) * | 2012-06-01 | 2014-12-19 | Galderma Res & Dev | Compositions topiques, contenant un retinoide, de type emulsion huile dans eau sans emulsionnant |
FR2991172A1 (fr) * | 2012-06-01 | 2013-12-06 | Galderma Res & Dev | Compositions pharmaceutiques topiques comprenant des microcapsules |
WO2017194486A1 (en) | 2016-05-12 | 2017-11-16 | Unilever Plc | Method for stabilizing retinoic acid precursors and a skin benefit composition with stabilized retinoic acid precursors |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0651619B2 (ja) * | 1988-05-09 | 1994-07-06 | 株式会社クラレ | 美白剤 |
FR2723315B1 (fr) * | 1994-08-02 | 1996-10-25 | Cird Galderma | Procede et composition pour stimuler la differenciation des cellules preadipocytaires et traitements therapeutiques associes |
FR2752734B1 (fr) * | 1996-09-02 | 1998-11-06 | Cird Galderma | Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf |
JP2001206813A (ja) * | 2000-01-27 | 2001-07-31 | Pola Chem Ind Inc | 物理的治療用の皮膚外用剤 |
US20030003142A1 (en) * | 2001-05-23 | 2003-01-02 | Wortzman Mitchell S. | Composition and method for the treatment of pigmentation disorders |
AU2003270272B2 (en) * | 2002-09-05 | 2008-06-19 | Galderma Research & Development, S.N.C. | Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent |
MXPA05005170A (es) * | 2002-12-12 | 2005-10-05 | Galderma Res & Dev | Gel despigmentante alcoholico acuoso que contiene un derivado fenolico y un retinoide. |
AU2004296694C1 (en) * | 2003-12-15 | 2011-05-19 | Kuraray Co., Ltd. | External preparations for skin |
FR2871377B1 (fr) * | 2004-06-11 | 2007-08-24 | Galderma Res & Dev | Gel depigmentant hydroalcoolique comprenant du mequinol et de l'adapalene |
PL1831149T3 (pl) * | 2004-12-23 | 2012-06-29 | Galderma Res & Dev | Nowe ligandy, które modulują receptory RAR, i ich zastosowanie w medycynie i kosmetyce |
FR2889662B1 (fr) * | 2005-08-11 | 2011-01-14 | Galderma Res & Dev | Emulsion de type huile-dans-eau pour application topique en dermatologie |
-
2007
- 2007-05-04 FR FR0754886A patent/FR2915682B1/fr not_active Expired - Fee Related
-
2008
- 2008-04-22 KR KR1020097023026A patent/KR20100016204A/ko not_active Application Discontinuation
- 2008-04-22 BR BRPI0809880-8A patent/BRPI0809880A2/pt not_active IP Right Cessation
- 2008-04-22 RU RU2009144988/15A patent/RU2009144988A/ru not_active Application Discontinuation
- 2008-04-22 WO PCT/FR2008/050731 patent/WO2008148968A1/fr active Application Filing
- 2008-04-22 AU AU2008259754A patent/AU2008259754A1/en not_active Abandoned
- 2008-04-22 MX MX2009011743A patent/MX2009011743A/es not_active Application Discontinuation
- 2008-04-22 JP JP2010506973A patent/JP2010526124A/ja active Pending
- 2008-04-22 CA CA002685482A patent/CA2685482A1/fr not_active Abandoned
- 2008-04-22 EP EP08805686A patent/EP2167061A1/fr not_active Withdrawn
- 2008-04-22 CN CN200880014227A patent/CN101674818A/zh active Pending
-
2009
- 2009-11-04 US US12/588,972 patent/US20100143445A1/en not_active Abandoned
-
2012
- 2012-07-17 US US13/551,437 patent/US20120282314A1/en not_active Abandoned
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101791282B (zh) * | 2009-12-29 | 2013-09-25 | 广东药学院 | 一种美容换肤液及其制备方法和应用 |
CN101961299A (zh) * | 2010-09-28 | 2011-02-02 | 清华大学 | 一种中草药凝胶化妆品及其制备方法 |
CN101961299B (zh) * | 2010-09-28 | 2014-04-02 | 清华大学 | 一种中草药凝胶化妆品及其制备方法 |
CN104507470A (zh) * | 2012-06-01 | 2015-04-08 | 盖尔德马研究及发展公司 | 含有类维生素a的o/w乳液类型的局部药物组合物 |
CN110868993A (zh) * | 2017-07-12 | 2020-03-06 | 荷兰联合利华有限公司 | 皮肤组合物增效油 |
Also Published As
Publication number | Publication date |
---|---|
KR20100016204A (ko) | 2010-02-12 |
EP2167061A1 (fr) | 2010-03-31 |
MX2009011743A (es) | 2009-11-11 |
CA2685482A1 (fr) | 2008-12-11 |
JP2010526124A (ja) | 2010-07-29 |
US20100143445A1 (en) | 2010-06-10 |
RU2009144988A (ru) | 2011-06-10 |
AU2008259754A1 (en) | 2008-12-11 |
US20120282314A1 (en) | 2012-11-08 |
FR2915682B1 (fr) | 2009-07-03 |
FR2915682A1 (fr) | 2008-11-07 |
WO2008148968A1 (fr) | 2008-12-11 |
BRPI0809880A2 (pt) | 2014-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101674818A (zh) | 皮肤病学和化妆品去色素组合物、其制备方法和其用途 | |
Lee et al. | Basic chemical peeling: superficial and medium-depth peels | |
JP2010095534A (ja) | フェノール誘導体およびレチノイド含有水−アルコール脱色ゲル | |
EP1536763B1 (en) | Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent | |
JP2008501769A (ja) | メキノール及びアダパレンを含む水性−アルコールの脱色性ゲル | |
AU2009309687A1 (en) | Depigmenting topical compositions and their uses | |
Glaser et al. | Topical and systemic therapies for the aging face | |
CN100464741C (zh) | 含有酚衍生物和类维生素a的含水醇脱色素凝胶 | |
WO2015011311A1 (es) | Combinación para disminuir la hiperpigmentación de la piel | |
Patel | FACIAL MELANOSES-HYPERPIGMENTARY DISORDERS | |
US20070129446A1 (en) | Use of fepradinol for the production of a pharmaceutical composition for the treatment of rosacea | |
JP2002047169A (ja) | 植物由来の美白化粧料 | |
ES2311874T3 (es) | Utilizacion de idrocilamida para la preparacion de una composicion farmaceutica para el tratamiento de la rosacea. | |
Handog et al. | Melasma | |
KR20220004071A (ko) | 이소프로필카보네이트 벤조일 퍼옥사이드 조성물 및 사용 방법 | |
Dharmana | Review of topical lightening agents | |
CA3217338A1 (en) | Topical formulations comprising benzoyl peroxide and azelaic acid, and use thereof | |
US20070149620A1 (en) | Use of piketprofen for the preparation of a pharmaceutical composition to treat rosacea | |
WO2024056568A1 (en) | Skin depigmentation composition and use thereof | |
CN104039301A (zh) | 丹涅酮及其衍生物在皮肤护理中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1141438 Country of ref document: HK |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20100317 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1141438 Country of ref document: HK |